FDA declines Summit’s ivonescimab application
The U.S. Food and Drug Administration declined Summit Therapeutics’ application for ivonescimab with chemotherapy for a group of previously treated lung cancer patients, saying the trial did not show a statistically significant improvement in overall survival. The decision leaves the proposed treatment without U.S. approval for patients with EGFR-mutated, nonsquamous non-small cell lung cancer whose disease progressed after a third-generation EGFR inhibitor.
The FDA’s complete response letter said the progression-free-survival benefit alone did not establish a favorable benefit-risk profile, according to Summit’s account. Progression-free survival measures how long patients live without their cancer worsening; overall survival measures how long they live after starting treatment. The agency’s decision was based on the primary overall-survival analysis in the global Phase 3 HARMONi trial.
In that study, median progression-free survival was 6.8 months for patients receiving ivonescimab plus chemotherapy, compared with 4.4 months for those receiving chemotherapy alone. The combination reduced the risk of disease progression or death by 48%, according to the trial results. However,...